Harvard Business Review

OCTOBER 26, 2011

Solyndra's example has been particularly stark: it raised over $1 billion in equity finance in addition to receiving a $535 million loan guarantee from the Department of Energy, all prior to a cancelled IPO and the recent FBI investigation upon its bankruptcy.

Energy 15

Energy Finance IPO Biotechnology 15

Harvard Business Review

APRIL 16, 2012

This raises the question of whether retaining strategic cash makes economic sense and should be viewed as a legitimate corporate finance tool in today's environment. Strategic cash also can be used to finance long-term reinvestment programs in the business—which is especially valuable to companies in capital-intensive industries (e.g.,

Company 15

Company Cost of Capital Finance Long-term 15

Harvard Business Review

MAY 20, 2014

financial services sector went from 13,000 of independent banks to half that number, while the top ten banks grew from 20% market share to 60%. As of 2013, the top ten banks had 70% of the market. In pharmaceuticals, the largest company, Pfizer, is the result of decades of mergers. Economy Entrepreneurship Finance'

Pharmaceuticals 14

Pharmaceuticals Banking Chemicals Entrepreneur 14

Harvard Business Review

AUGUST 29, 2011

We discovered some of these pushes and pulls in our research for our upcoming book, Winning the War for Talent in Emerging Markets: Why Women Are the Solution. There's a sense that a woman is just working until she gets married, [that] she is not a long-term resource," said one senior finance professional. We do all of them.".

Stress 19

Stress Human Resources Pharmaceuticals Finance 19

Harvard Business Review

OCTOBER 13, 2011

Bank marketing materials focus on the dreams, anxieties and goals of consumers. The pharmaceutical industry also creates products with complex interactions and potentially dangerous side effects. Yet unlike in finance, where distributing risk across institutions is the goal, in drug development the focus is on isolating risk.

Banking 14

Banking Pharmaceuticals Microfinance Risk Management 14

Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves. As yet, the facts don't seem to substantiate the fears.

Licensing 15

Licensing Depreciation Pharmaceuticals Budgeting 15

Harvard Business Review

AUGUST 2, 2011

In reality, each country needs the other to succeed in order to thrive — to finance growth, secure export markets, train talent, transfer technology, and more. For example, pharmaceutical firms license compounds to each other and co-promote products in different markets.

Apparel 16

Apparel Pharmaceuticals Finance Licensing 16

Harvard Business Review

AUGUST 8, 2018

As chief executive from 1972 to 1994, Richard Gelb (HBS, 1950) orchestrated Bristol-Myers’ acquisition of Squibb and transformed the firm from a personal care company to a diversified pharmaceutical giant. In another supplementary analysis, we used the rankings of finance departments in business schools.

Influence 15

Influence Education Pharmaceuticals Finance 15

Harvard Business Review

JANUARY 10, 2013

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Finance 11

Finance Banking Press Release Pharmaceuticals 11

Harvard Business Review

NOVEMBER 9, 2011

COOs are relatively common in service industries such as financial services, energy, information technology and telecommunications, but in manufacturing sectors — such as automotive, chemical, and pharmaceutical companies — they are relatively rare.

COO 16

COO Sample Telecommunications Automotive 16

Harvard Business Review

APRIL 5, 2012

If you spend much time around salespeople, it won't take long before you hear them griping about the issue that is the profession's biggest trouble spot: disagreement over the market potential of a group of accounts or a territory. In exit interviews, the people who leave imply they don't have enough market potential to succeed.".

Retail 13

Retail Incentives Tactics Pharmaceuticals 13

Harvard Business Review

AUGUST 23, 2012

For highly regulated sectors like finance, social media can be a legal minefield. These hurdles aren't unique to financial services — insurance, pharmaceuticals, health care and government all face regulation, to name a few examples. "Follow us here for updates on our work, our research, and our people.".

Compliance 17

Compliance Media Compliance Officer Policies 17

Harvard Business Review

JULY 4, 2017

With that in mind, I can see three potential scenarios for how Apple might play in the autonomous car market. Some of them may never enter the car market, or may at least significantly delay a move toward ownership. Apple has a great intuitive feel for how consumers see a market, versus how manufacturers see it. Or a kitchen?

Transportation 14

Transportation Sports Pharmaceuticals Health Care 14

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares.

Long-term 15

Long-term Sample Pharmaceuticals Report 15

Harvard Business Review

MARCH 24, 2011

Competitors whispered that Gupta was committing the most un-McKinsey-like of sins: cutting price to get into new markets. As the stock market began to take off, though, and options rained down on corporate execs, the compensation tables began to turn, certainly for the top ranks. And what risks did he run? At the very least, contagion.

McKinsey 16

McKinsey Consultative Waterman Intellectual Capital 16

Harvard Business Review

OCTOBER 24, 2014

In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. It also took into account their roles in changing patient behavior.

Products 10

Products Productivity Company Engineering 10

Harvard Business Review

SEPTEMBER 13, 2011

Here are some common examples: When pharmaceutical companies announce that a new drug has been "approved," they are actually saying that their researchers made some breakthrough discoveries as far back as fifteen years ago. Financial firms that report quarterly earnings are probably jumping the gun with their results.

Short-term 15

Short-term Pharmaceuticals Long-term Maturity 15

Harvard Business Review

SEPTEMBER 4, 2015

We’ve found that CEOs of big pharmaceutical companies, for example, are more likely to have a background as company lawyers, salespeople, or finance managers, than one in medicine or pharmaceutical R&D. Pharmaceuticals. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

APRIL 2, 2018

There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations. (For

Health Care 9

Health Care Insurance Pharmaceuticals Incentives 9

Harvard Business Review

OCTOBER 25, 2018

We focus on economic profit rather than revenue size, market share, or productivity growth because these other metrics risk including firms that are simply large and may not create economic value. (To do this, we take the firm’s returns, deduct the cost of capital, and multiply by the firm’s total invested capital.)

Industry 15

Industry Company GDP Bottom-up 15

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it''s a wonder we have any innovative products at all. They illustrate the range of programs that companies should be implementing to stimulate innovation and shepherd ideas toward marketable products. Finance Innovation' It''s like that. Ready to Innovate?

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it’s a wonder we have any innovative products at all. They illustrate the range of programs that companies should be implementing to stimulate innovation and shepherd ideas toward marketable products. Finance Innovation Insight Center_Innovation no-intromercial'

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

OCTOBER 20, 2016

Meanwhile the Institute of International Finance forecasted net capital flows for emerging markets in 2015 would be negative for the first time since 1988. pharmaceutical company, had to abandon its $106 billion attempt to buy British drug maker AstraZeneca in the face of opposition from UK politicians.

Globalization 8

Globalization Banking Policies Politics 8

Harvard Business Review

FEBRUARY 4, 2013

Just under 1,000 companies account for half of the world's market capitalization, Eccles notes. Breakthrough requires an end to systemic inequities by opening up processes, information - and markets. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Finance.

EPS 9

EPS Innovation CEO Pharmaceuticals 9

Harvard Business Review

MAY 1, 2013

Without adequate financing, ministries of health and even private hospitals in developing countries often don''t have the resources needed to purchase diagnostic equipment, train workers, and ensure access to appropriate treatment. Three people die every minute from tuberculosis — a treatable and largely preventable disease.

Health Care 8

Health Care ROI NGO Long-term 8

Harvard Business Review

JUNE 16, 2016

In July 2015, Novartis launched its new heart failure drug, Entresto, which Forbes in 2014 predicted would be a blockbuster — with expected sales of $10 billion annually — as the potential market in the US exceeds 5 million people with a heart failure condition. The failure stemmed from resistance in the U.S.

Planning 8

Planning Competitive Intelligence Pharmaceuticals Brand 8

Harvard Business Review

NOVEMBER 20, 2015

He is poised to become the leader in this segment of a multi-billion dollar market. Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

JUNE 29, 2015

If you ask someone who works in finance (as I had to) about PE and innovation, he or she will likely tell you that PE sponsors aren’t looking for the next big thing—they’re looking for companies that are dominant in a market, aren’t risky, and have a predictable and steady stream of cash to pay back debt.

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 19, 2016

This logic and the institutions that reinforce it, like competitive markets and the rule of law, have transformed the world and lifted billions of people from poverty. Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. How should you make this decision?

ROI 8

ROI Long-term Pharmaceuticals Conflict of Interest 8

Harvard Business Review

FEBRUARY 26, 2013

An "earn-your-way" strategy is sometimes necessary in markets with high uncertainty or when a company is cash-strapped. But when leaders take this conservative growth approach even when there is reasonable certainty of success and available financing, they undersize their sales forces and forfeit opportunity.

Company 8

Company Short-term Long-term Cost 8

Harvard Business Review

SEPTEMBER 21, 2015

Terry, a highly regarded marketing associate in a pharmaceutical firm, had just been asked to lead a marketing team. To do this, Terry drew on her own experience as a star marketer. This way, any information her team needed from finance, sales, or any other department would arrive on time and in the specified format.

Management 8

Management Pharmaceuticals Learning-by-Doing Marketing 8

Harvard Business Review

MAY 5, 2016

But peruse some of the recent headlines about Iran , and you might wonder whether the market’s potential was overstated. However, despite a weakened economy, political tensions, market uncertainty, and the lingering effects of sanctions, Iran remains an important opportunity for multinationals in emerging markets.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. What would be the cost/benefit of flattening your supply chain and moving production closer to your markets? How could digital printing improve your innovation, product development, and speed to market?

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

JANUARY 26, 2016

And yet for almost every company that uses CI in their decision-making, there’s another that disregards CI’s mix of industry analysis, rival positions, and market insight to their detriment. and European corporations, from CI-trained analysts in marketing, business development, strategy, R&D, finance, and other fields.

Competitive Intelligence 8

Competitive Intelligence Company CAPEX Analysis 8

Harvard Business Review

FEBRUARY 20, 2014

But an awful lot of these jobs command very high-wages in law, finance, accounting, consulting, advertising, engineering, design, software, healthcare, scientific research, architecture, entertainment, hospitality, and many other areas. True, emerging market countries are getting better at what they do, and even Europe is on the upswing.

Intellectual Capital 9

Intellectual Capital Magazine Pharmaceuticals Creativity 9

Harvard Business Review

AUGUST 6, 2015

I made a career switch seven years ago, when I went from working as a reporter at the Financial Times , where I covered health care in the United States, to consulting — advising CEOs in the pharmaceutical industry on thought leadership and articulating their corporate strategies. You should also ask: How you should market them?

Career 8

Career Skills Health Care Pharmaceuticals 8